Type 2 Diabetes MellitusDISCOVERNCT02322762

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

An observational study of Type 2 Diabetes Mellitus, run by AstraZeneca at 303 sites in 32 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

DISCOVER is a Non Interventional Study study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Type 2 Diabetes Mellitus
How many people: 15,992 participants
Where: 303 sitesin 32 countries
Study dates: 30 Dec 2014to 21 Aug 2019
Phase: Observational
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: Patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy. Participating investigators will belong to primary, secondary or tertiary care clinics or hospitals in proportions trying to resemble the reality of management of this type of patients in each country.

Who may be able to join

Provision of subject informed consent
Female or male aged 18 years and over
Diagnosed with type 2 diabetes mellitus
Initiating a second line anti-diabetic therapy, either as add-on, or switching from one monotherapy to another.

Who cannot join

Diagnosis of type 1 diabetes mellitus
Patient is pregnant
Patients initiating a dual therapy after having previously received two different lines of monotherapy before (e.g.: Metformin → SU (Sulphonylureas) → SU+Add-on)
Current treatment with chemotherapy, oral or iv steroids
Patient is on dialysis or has had a renal transplant
The patient is taking insulin as first line treatment

Show all 11Show fewer

The patient is taking dual therapy or a fixed dose combination treatment as first line treatment.
The patient is taking herbal remedies / natural medicines as first line treatment
Participation in an interventional trial
Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient for 3 years (e.g. lifethreatening co-morbidities, tourist, non-native speaker or does not understand the local language where interpreter services are not reliably available, psychiatric disturbances, dementia, alcohol or drug abuse).
Not willing to sign the informed consent.

Trial locations and contacts

303 sites in 32 countries.

Country

City, postcode or hospital

303 sites in 32 countries

Netherlands32 sites

Research Site
Almelo
Research Site
Alpen Aan Den Rijn
Research Site
Amersfoort
Research Site
Amsterdam
Research Site
De Bilt
Research Site
Doetinchem
Research Site
Dordrecht
Research Site
Dorst
Research Site
Elst
Research Site
Enschede
Research Site
Etten-Leur
Research Site
Garderen
Research Site
Geleen
Research Site
Gouda
Research Site
Hoogezand
Research Site
Katwijk
Research Site
Kerkrade
Research Site
Kloosterhaar
Research Site
Landgraaf
Research Site
Luttenberg
Research Site
Nijverdal
Research Site
Oisterwijk
Research Site
Roermond
Research Site
Soerendonk
Research Site
Steenbergen
Research Site
The Hague
Research Site
Utrecht
Research Site
Vaassen
Research Site
Voerendaal
Research Site
Wamel
Research Site
Zoetermeer
Research Site
Zundert

Other trials in Netherlands

China22 sites

Research Site
Beijing
Research Site
Changsha
Research Site
Chengdu
Research Site
Chenzhou
Research Site
Chongqing
Research Site
Fuzhou
Research Site
Guangzhou
Research Site
Guiyang
Research Site
Hefei
Research Site
Kunming
Research Site
Lanzhou
Research Site
Nanjing
Research Site
Panjin
Research Site
Shanghai
Research Site
Shantou
Research Site
Shijiazhuang
Research Site
Shiyan
Research Site
Suzhou
Research Site
Tianjin
Research Site
Ürümqi
Research Site
Wuhan
Research Site
Wuxi

Other trials in China

India19 sites

Research Site
Bangalore
Research Site
Chandigarh
Research Site
Chennai
Research Site
Coimbatore
Research Site
Delhi
Research Site
Ghaziabad
Research Site
Gūrgaon
Research Site
Hyderabad
Research Site
Indore
Research Site
Jaipur
Research Site
Kanpur
Research Site
Karnāl
Research Site
Kolkata
Research Site
Mangalore
Research Site
Mumbai
Research Site
Nagpur
Research Site
Noida
Research Site
Pune
Research Site
Trivandrum

Other trials in India

Turkey (Türkiye)16 sites

Research Site
Adana
Research Site
Afyonkarahisar
Research Site
Antalya
Research Site
Çanakkale
Research Site
Çorum
Research Site
Denizli
Research Site
Diyarbakır
Research Site
Düzce
Research Site
Elâzığ
Research Site
Gaziantep
Research Site
Hatay
Research Site
Istanbul
Research Site
Izmir
Research Site
Karaman
Research Site
Kayseri
Research Site
Samsun

Other trials in Turkey (Türkiye)

Australia14 sites

Research Site
Blacktown
Research Site
Burwood
Research Site
Castle Hill
Research Site
Coorparoo
Research Site
Corio
Research Site
Cowra
Research Site
Edmonton
Research Site
Forbes
Research Site
Garran
Research Site
Ipswich
Research Site
Melbourne
Research Site
Sherwood
Research Site
Smithfield
Research Site
South Lake

Other trials in Australia

Czechia14 sites

Research Site
Benátky nad Jizerou
Research Site
Beroun
Research Site
Broumov
Research Site
Dolní Břežany
Research Site
Karlovy Vary
Research Site
Krnov
Research Site
Litoměřice
Research Site
Náchod
Research Site
Olomouc
Research Site
Ostrava
Research Site
Pilsen
Research Site
Prague
Research Site
Uherské Hradiště
Research Site
Újezd u Brna

Other trials in Czechia

Brazil13 sites

Research Site
Belo Horizonte
Research Site
Brasília
Research Site
Campina Grande do Sul
Research Site
Campinas
Research Site
Curitiba
Research Site
Fortaleza
Research Site
Juiz de Fora
Research Site
Porto Alegre
Research Site
Rio de Janeiro
Research Site
Santa Maria
Research Site
São José do Rio Preto
Research Site
São José dos Campos
Research Site
São Paulo

Other trials in Brazil

Italy11 sites

Research Site
Foggia
Research Site
Garbagnate Milanese
Research Site
Livorno
Research Site
Mariano Comense
Research Site
Parma
Research Site
Pavia
Research Site
Pisa
Research Site
Potenza
Research Site
Rimini
Research Site
Roma
Research Site
Sesto San Giovanni

Other trials in Italy

Malaysia11 sites

Research Site
Alor Star
Research Site
Ayer Itam
Research Site
Ipoh
Research Site
Johor Bahru
Research Site
Kelantan
Research Site
Kuala Krai
Research Site
Masjid Tanah
Research Site
Miri
Research Site
Perak
Research Site
Sandakan
Research Site
Seremban

Other trials in Malaysia

Poland11 sites

Research Site
Chorzów
Research Site
Elblag
Research Site
Gdansk
Research Site
Katowice
Research Site
Krakow
Research Site
Lodz
Research Site
Lublin
Research Site
Parczew
Research Site
Rzeszów
Research Site
Zabrze
Research Site
Zgierz

Other trials in Poland

Russia11 sites

Research Site
Arkhangelsk
Research Site
Barnaul
Research Site
Moscow
Research Site
Nizhny Novgorod
Research Site
Novosibirsk
Research Site
Rostov-on-Don
Research Site
Saint Petersburg
Research Site
Saratov
Research Site
Sestroretsk
Research Site
Stavropol
Research Site
Yaroslavl

Other trials in Russia

South Africa11 sites

Research Site
Alberton
Research Site
Cape Town
Research Site
Durban
Research Site
eMkhomazi
Research Site
Johannesburg
Research Site
Lenasia
Research Site
Merebank
Research Site
Midstream
Research Site
Moloto South
Research Site
Port Elizabeth
Research Site
Pretoria

Other trials in South Africa

Spain11 sites

Research Site
Barcelona
Research Site
Cadiz
Research Site
Elche
Research Site
Espinardo
Research Site
Madrid
Research Site
Móstoles
Research Site
Salamanca
Research Site
Sanlúcar de Barrameda
Research Site
Segovia
Research Site
Seville
Research Site
Valencia

Other trials in Spain

Tunisia11 sites

Research Site
Gabès
Research Site
Kairaouane
Research Site
Mahdia
Research Site
Montfleury
Research Site
Mutuelleville
Research Site
Nabeul
Research Site
Sfax
Research Site
Sousse
Research Site
Sukrah
Research Site
Tunis
Research Site
Tunis Belvedere

Other trials in Tunisia

South Korea10 sites

Research Site
Bucheon-si
Research Site
Cheonan-si
Research Site
Chuncheon
Research Site
Daejeon
Research Site
Goyang-si
Research Site
Gwangmyeong
Research Site
Iksan
Research Site
Jeju Special Self-Governing Province
Research Site
Seongnam-si
Research Site
Seoul

Other trials in South Korea

Argentina9 sites

Research Site
Buenos Aires
Research Site
Chacabuco
Research Site
Ciudad Autonoma Buenos Aires
Research Site
Córdoba
Research Site
Corrientes
Research Site
Paraná
Research Site
Rosario
Research Site
San Miguel de Tucumán
Research Site
Santa Fe

Other trials in Argentina

Indonesia9 sites

Research Site
Balikpapan
Research Site
Banda Aceh
Research Site
Batu
Research Site
Bekasi Timur
Research Site
Denpasar
Research Site
Jakarta
Research Site
Malang
Research Site
Manado
Research Site
Padang

Other trials in Indonesia

Mexico9 sites

Research Site
Acapulco de Juárez
Research Site
Aguascalientes
Research Site
Chihuahua City
Research Site
Guadalajara
Research Site
México
Research Site
Monterrey
Research Site
San Juan del Río
Research Site
Tamaulipas
Research Site
Zapopan

Other trials in Mexico

Austria8 sites

Research Site
Feldbach
Research Site
Graz
Research Site
Innsbruck
Research Site
Linz
Research Site
Salzburg
Research Site
Sankt Veit im Pongau
Research Site
Stankt Stefan Ob Stainz
Research Site
Vienna

Other trials in Austria

Egypt8 sites

Research Site
Al Mansurah
Research Site
Alexandria
Research Site
Asyut
Research Site
Cairo
Research Site
Giza
Research Site
Heliopolis
Research Site
Minya
Research Site
Tanta

Other trials in Egypt

Lebanon8 sites

Research Site
Beirut
Research Site
Byblos
Research Site
Chtoura
Research Site
Hamra
Research Site
Mazraat Yachouaa
Research Site
Saida
Research Site
Tripoli
Research Site
Tyre

Other trials in Lebanon

Algeria6 sites

Research Site
Algiers
Research Site
Batna City
Research Site
Blida
Research Site
Constantine
Research Site
Oran
Research Site
Sétif

Other trials in Algeria

Taiwan6 sites

Research Site
Changhua
Research Site
Kaohsiung City
Research Site
New Taipei City
Research Site
Taichung
Research Site
Tainan
Research Site
Taipei

Other trials in Taiwan

Colombia5 sites

Research Site
Barranquilla
Research Site
Bogotá
Research Site
Cali
Research Site
Manizales
Research Site
Medellín

Other trials in Colombia

Saudi Arabia5 sites

Research Site
Abhā
Research Site
Al Jouf
Research Site
Jeddah
Research Site
Khamis Mushait
Research Site
Riyadh

Other trials in Saudi Arabia

Costa Rica3 sites

Research Site
Cartago
Research Site
Heredia
Research Site
San José

Other trials in Costa Rica

Jordan3 sites

Research Site
Amman
Research Site
Az Zarqaa
Research Site
Irbid

Other trials in Jordan

Panama2 sites

Research Site
Calle
Research Site
Coclé

Other trials in Panama

United Arab Emirates2 sites

Research Site
Abu Dhabi
Research Site
Dubai

Other trials in United Arab Emirates

Bahrain1 site

Research Site
Bahrain

Other trials in Bahrain

Kuwait1 site

Research Site
Kuwait City

Other trials in Kuwait

Oman1 site

Research Site
Muscat

Other trials in Oman

About this study

Read the detailed description

DISCOVER is a NIS study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment. This study is a multi-country, multicenter, observational, prospective, longitudinal cohort study. The patients will be recruitted from countries in Latin America, Europe and Asia pac. It is estimated that approximately 13350 patients will be enrolled in total with each patient followed up for 3 years.

Conditions: Type 2 Diabetes Mellitus
Keywords: Type 2 diabetes mellitus, Anti-diabetic management patterns
Medical subject headings: Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02322762
Study group	Role	What they receive
One single cohort.		One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.

What is being measured

The primary outcome is the main question the study is designed to answer.

Anti-diabetic treatments prescribed by physicians in a real-world setting.
The drugs (or their combinations) prescribed by physicians to patients initiating a 2nd line anti-diabetic treatment in a real-world setting will be described at inclusion and during 3 years follow-up.
Measured: Up to 3 Years

Secondary outcomes (6)

Disease control in terms of achieving HbA1c target goals and reducing body weight and blood pressure.
Measured: Up to 3 years
Changes in anti-diabetic treatments
Measured: Up to 3 years
Disease progression (incidence of microvascular and macrovascular complications).
Measured: Up to 3 years
Incidence of hypoglycemic events.
Measured: Up to 3 years
Quality of Life, using Patient Reported Outcomes questionnaires.
Measured: Up to 3 years
Use of Healthcare resources.
Measured: Up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Dec 201421 Aug 2019

First posted23 Dec 2014 (estimated)
Study start30 Dec 2014
Primary completion21 Aug 2019
Study completion21 Aug 2019

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (10)Papers the sponsor has linked to this study.
Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Prospective
Enrolment: 15,992 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02322762
Sponsor's protocol ID: D1690R00002
Acronym: DISCOVER
Status last verified: Jun 2022
First submitted: 19 Dec 2014
Last updated: 9 Jun 2022
Results posted: No
Data monitoring committee: No

Publications

Al Rubeaan K, Banah F, Alruwaily FG, Sheshah E, Alnaqeb D, AlQahtani AM, Ewais D, Al Juhani N, Hassan AH, Youssef AM. Metabolic control and incidence of hypoglycaemia, hospitalisation and complications among Saudi patients with type 2 diabetes initiating second-line therapy: an analysis of the Saudi Arabia data from the DISCOVER Observational Study programme. BMJ Open. 2023 Aug 30;13(8):e063586. doi: 10.1136/bmjopen-2022-063586.
PubMed 37648382
Al-Rubeaan K, Banah F, Alruwaily FG, Sheshah E, Alnaqeb D, AlQahtani AM, Ewais D, Al Juhani N, Hassan AH, Youssef AM. Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study. Curr Med Res Opin. 2023 Jan;39(1):27-35. doi: 10.1080/03007995.2022.2144052. Epub 2022 Nov 28.
PubMed 36342972
Mita T, Katakami N, Takahara M, Kawashima M, Wada F, Akiyama H, Morita N, Kidani Y, Yajima T, Shimomura I, Watada H. Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment. J Clin Endocrinol Metab. 2022 Aug 18;107(9):2424-2432. doi: 10.1210/clinem/dgac420.
PubMed 35857060
Hejjaji V, Gorgojo-Martinez JJ, Tang F, Garnelo JB, Cooper A, Medina J, Mutiozabal MS, Khunti K, Nicolucci A, Shestakova MV, Ji L, Gomes MB, Watada H, Vora J, Malik AO, Kosiborod M, Arnold SV. Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. Diabetes Obes Metab. 2022 Sep;24(9):1734-1740. doi: 10.1111/dom.14745. Epub 2022 May 25.
PubMed 35546275
Khunti K, Gomes MB, Kosiborod M, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Tang F, Ji L; DISCOVER Scientific Committee and all DISCOVER investigators. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. BMJ Open. 2020 Aug 30;10(8):e034613. doi: 10.1136/bmjopen-2019-034613.
PubMed 32868349
Wang JS, Chen H, Tang F, Sheu WH. Associations of fear of hypoglycemia with second-line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study. Int J Clin Pract. 2020 Jun;74(6):e13485. doi: 10.1111/ijcp.13485. Epub 2020 Feb 11.
PubMed 32003099
Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1.
PubMed 31468637
Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5.
PubMed 31297947
Khunti K, Ji L, Medina J, Surmont F, Kosiborod M. Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. Diabetes Obes Metab. 2019 Nov;21(11):2349-2353. doi: 10.1111/dom.13817. Epub 2019 Jul 14.
PubMed 31215715
Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8.
PubMed 30486889

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

All Type 2 Diabetes Mellitus trials

Study at a glance

From the registry record, last updated by the sponsor on 9 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
ClinicalTrials.gov ID: NCT02322762
Acronym / sponsor ID: DISCOVER / D1690R00002
Conditions: Type 2 Diabetes Mellitus
Keywords: Type 2 diabetes mellitus, Anti-diabetic management patterns
Study type: Observational
Recruitment status: Completed
Enrolment: 15,992 participants (actual)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 30 Dec 2014 (actual)
Primary completion: 21 Aug 2019 (actual)
Study completion: 21 Aug 2019 (actual)
First posted: 23 Dec 2014 (estimated)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Observational model: Cohort
Time perspective: Prospective
Number of arms: 1

Arm	Type	Receives
One single cohort.	–	–One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy. Participating investigators will belong to primary, secondary or tertiary care clinics or hospitals in proportions trying to resemble the reality of management of this type of patients in each country.

Key inclusion criteria (4 listed)

Provision of subject informed consent
Female or male aged 18 years and over
Diagnosed with type 2 diabetes mellitus
Initiating a second line anti-diabetic therapy, either as add-on, or switching from one monotherapy to another.

Key exclusion criteria (11 listed)

Diagnosis of type 1 diabetes mellitus
Patient is pregnant
Patients initiating a dual therapy after having previously received two different lines of monotherapy before (e.g.: Metformin → SU (Sulphonylureas) → SU+Add-on)
Current treatment with chemotherapy, oral or iv steroids
Patient is on dialysis or has had a renal transplant

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

Anti-diabetic treatments prescribed by physicians in a real-world setting.
Time frame: Up to 3 Years
The drugs (or their combinations) prescribed by physicians to patients initiating a 2nd line anti-diabetic treatment in a real-world setting will be described at inclusion and during 3 years follow-up.

6 secondary outcomes

Disease control in terms of achieving HbA1c target goals and reducing body weight and blood pressure.
Time frame: Up to 3 years
Changes in anti-diabetic treatments
Time frame: Up to 3 years
Disease progression (incidence of microvascular and macrovascular complications).
Time frame: Up to 3 years
Incidence of hypoglycemic events.
Time frame: Up to 3 years
Quality of Life, using Patient Reported Outcomes questionnaires.
Time frame: Up to 3 years
Use of Healthcare resources.
Time frame: Up to 3 years

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2022.
Derived from this study: PubMed 37648382Al Rubeaan K, Banah F, Alruwaily FG, Sheshah E, Alnaqeb D, AlQahtani AM, Ewais D, Al Juhani N, Hassan AH, Youssef AM. Metabolic control and incidence of hypoglycaemia, hospitalisation and complications among Saudi patients with type 2 diabetes initiating second-line therapy: an analysis of the Saudi Arabia data from the DISCOVER Observational Study programme. BMJ Open. 2023 Aug 30;13(8):e063586. doi: 10.1136/bmjopen-2022-063586.
Derived from this study: PubMed 36342972Al-Rubeaan K, Banah F, Alruwaily FG, Sheshah E, Alnaqeb D, AlQahtani AM, Ewais D, Al Juhani N, Hassan AH, Youssef AM. Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study. Curr Med Res Opin. 2023 Jan;39(1):27-35. doi: 10.1080/03007995.2022.2144052. Epub 2022 Nov 28.
Derived from this study: PubMed 35857060Mita T, Katakami N, Takahara M, Kawashima M, Wada F, Akiyama H, Morita N, Kidani Y, Yajima T, Shimomura I, Watada H. Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment. J Clin Endocrinol Metab. 2022 Aug 18;107(9):2424-2432. doi: 10.1210/clinem/dgac420.
Derived from this study: PubMed 35546275Hejjaji V, Gorgojo-Martinez JJ, Tang F, Garnelo JB, Cooper A, Medina J, Mutiozabal MS, Khunti K, Nicolucci A, Shestakova MV, Ji L, Gomes MB, Watada H, Vora J, Malik AO, Kosiborod M, Arnold SV. Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. Diabetes Obes Metab. 2022 Sep;24(9):1734-1740. doi: 10.1111/dom.14745. Epub 2022 May 25.
Derived from this study: PubMed 32868349Khunti K, Gomes MB, Kosiborod M, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Tang F, Ji L; DISCOVER Scientific Committee and all DISCOVER investigators. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. BMJ Open. 2020 Aug 30;10(8):e034613. doi: 10.1136/bmjopen-2019-034613.
Derived from this study: PubMed 32003099Wang JS, Chen H, Tang F, Sheu WH. Associations of fear of hypoglycemia with second-line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study. Int J Clin Pract. 2020 Jun;74(6):e13485. doi: 10.1111/ijcp.13485. Epub 2020 Feb 11.
Derived from this study: PubMed 31468637Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1.
Derived from this study: PubMed 31297947Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5.
Derived from this study: PubMed 31215715Khunti K, Ji L, Medina J, Surmont F, Kosiborod M. Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. Diabetes Obes Metab. 2019 Nov;21(11):2349-2353. doi: 10.1111/dom.13817. Epub 2019 Jul 14.
Derived from this study: PubMed 30486889Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8.
redacted CSR synopsisLink provided by the sponsor.

Related trials for Type 2 Diabetes Mellitus

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Jesus Medina, PhD study director

AstraZeneca

Linong Ji, MD principal investigator

Peking University People's Hospital, China

Bong Soo Cha, Dr. principal investigator

Severance Hospital, Yonsei University Health System

303 sites in 32 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Type 2 Diabetes Mellitus, run by AstraZeneca at 303 sites in 32 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 303 sites in Netherlands, China, India, Turkey (Türkiye), Australia and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anti-diabetic treatments prescribed by physicians in a real-world setting. (time frame: Up to 3 Years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02322762, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2022.